Comprehensive review on importance, challenges and future prospects of nanotechnology and combination therapy for Alzheimer’s disease

Abstract

Alzheimer's disease (AD) is a progressive neurological condition marked by memory or cognitive impairment, behavioral changes, visuospatial difficulties, decreased propensity to carry out day to day living tasks, and language impairment. Alzheimer's disease originated through neuronal cell loss over time. It generally begins in the hippocampus's entorhinal cortex. Various risk factor is related to AD, but only a few therapeutic approaches available to treat this neurodegenerative illness to help manage symptoms, limit disease development, avoid complications. Certain therapies from combination drug configuration and nanotechnology based medicine can increase the levels of specific neurotransmitters to slow the advancement damaging brain cells that may help to delay AD development. Yet any article was not published about the comparison between combination therapy and nanotechnology on Alzheimer treatment. This paper will show new researches about combining drugs for combination therapy and experiments with nanoparticles for investigating new nanotechnology based medicines for Alzheimer’s disease.